CME Advisory Committee Supports Medicare Payments for Provenge for Men Meeting the FDA Guidelines
The Centers for Medicare and Medicaid Services (CME) decided to review their policies pertaining to paying for Provenge, which costs $93,000 per man. Since the hearings which were held a number of months ago, we [...]
New Phase 2 Trials For MDV3100 Begins & Another To Start Soon – On The Horizon
It was announced today that the first patient in the TERRAIN study received their first dose in the Phase 2 trial of the investigational drug MDV3100 . MDV3100 is a triple-acting oral androgen receptor antagonist [...]
We Still need Your Support To Insure The Survival of the Prostate Cancer Research Program (PCRP)
I have been writing about the dire need for us to reach out to our congressional delegates and demand they support funding for the Prostate Cancer Research Program (PCRP). If you have not yet contacted [...]
Study Shows that Six Months of Neoadjuvant ADT Significantly Reduces Mortality in Locally Advanced Prostate Cancer
Researchers from the Trans-Tasman Radiation Oncology Group 96.01 trial study (TROG 96.01) concluded that six months of treatment with neoadjuvant androgen deprivation combined with radiation reduced the risk for disease-specific death by 49% in men [...]
The Latest on the Expanded Access Trial for Abiraterone- New Locations
ABIRATERONE EXPANDED ACCESS Trial Site Contact Info – 3/25/11 for men with advanced prostate cancer (800) 457-6399 M-F, 9am –5pm, EST TRIAL link: http://www.clinicaltrials.gov/ct2/show/NCT01217697?term=abiraterone&recr=Open&rank=6 Basic Criteria: 1. testosterone less than 50 2. metastatic prostate cancer [...]
Bristol-Myers Squibb Wins U.S. Approval for Ipilimumab to Treat Melanoma – Good News for Men with Advanced Prostate Cancer
Bristol-Myers Squibb Co. announced today (March 25) that it has received FDA approval for ipilimumab, the first drug in a new family of medicines to treat advanced melanoma, the most deadly form of skin cancer. [...]